

# Immune Mechanisms of Antipsychotic Treatment Response

NCT06687694

---

<b>Status</b>	RECRUITING
<b>Sponsor</b>	King's College London
<b>Enrollment</b>	500 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Participants with psychosis symptoms:
- Age 18-65
- Currently experiencing psychosis symptoms warranting treatment by secondary care mental health services, as confirmed by a psychiatrist involved in their treatment.
- Psychosis symptoms likely to be attributable to a disorder represented by ICD codes F20-F39, in the opinion of the treating clinical team.
- Due to start or change to a new regular antipsychotic medication. (Participants who are initiating antipsychotic treatment for the first time, transitioning to a different antipsychotic medication, or resuming a formerly prescribed antipsychotic medication that was discontinued for a minimum of two weeks may be recruited.)

... and 4 more (see full listing online)

### Exclusion (16)

- Participants with psychosis symptoms:
- Unacceptable risk of harm to participant or study staff due to risk of behavioural disturbance.
- Currently taking or having taken in the last four weeks any medication known to grossly affect the production or function of immune cells (e.g. corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, rituximab or other monoclonal antibody therapies).
- Inability to have blood tests.
- Control participants:

... and 11 more (see full listing online)

## Locations (1 total)

---

South London and Maudsley NHS Foundation Trust, London, United Kingdom, United Kingdom